MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dopaminergic neurons"

  • 2024 International Congress

    Slc2a13, a risk gene for Parkinson’s disease associated with Snca and Lrrk2

    JW. Li, GX. Zhang, T. Wang, ZC. Lin, N. Xiong (Wuhan, China)

    Objective: To exploit the potential function of the risk gene Slc2a13 in PD progression. Background: 越来越多的证据证实了总体遗传位点和候选基因对帕金森病的贡献,以及两个最确定的风险基因,即α-突触核蛋白(Snca)和富含亮氨酸的重复激酶2(Lrrk2)。Slc2a13 编码哺乳动物肌醇转运蛋白,被认为是一种群体依赖性风险基因。越来越多的证据支持这样一种观点,即 Slc2a13 活性的改变强调了 PD 的发展。剖析转运蛋白活性降低如何导致多巴胺能神经元变性和丧失,可能会进一步加深我们对功能的理解。 Method: A total of 338 cases…
  • 2023 International Congress

    The impact on religiosity following Deep Brain Stimulation (DBS) in patients with Essential Tremor (ET) and Parkinson’s Disease (PD)

    J. Frey, J. Lobo Lopes, M. Wajid, L. Kugler, C. Hess (Morgantown, USA)

    Objective: To determine the impact of DBS on religiosity. Background: Religiosity has been mapped to various brain networks1, 2, and transcranial magnetic stimulation has transiently…
  • 2023 International Congress

    Membrane-associated properties and ER stress alterations in LRRK2 I1371V patient iPSC derived neurons increase susceptibility to oxidative stress.

    S. Jagtap, I. Datta (Bengaluru, India)

    Objective: To evaluate the pathophysiology of the midbrain dopaminergic neurons (mDAN) derived from LRRK2 I1371V PD patient-iPSCs leading to susceptibility to oxidative stress. Background: Studies…
  • 2023 International Congress

    GT-02287, a brain-penetrant structurally targeted allosteric regulator for glucocerebrosidase shows evidence of pharmacological efficacy in an animal model of Parkinson’s disease.

    B. Calvo-Flores Guzman, N. Perez-Carmona, A. Garcia-Collazo, E. Cubero, X. Barril, M. Bellotto, J. Taylor (Lugano, Switzerland)

    Objective: To investigate the effect of the structurally targeted allosteric regulator GT-02287 on rotenone-induced neurotoxic effects in a Parkinson’s disease animal model. Background: Mutations in…
  • 2023 International Congress

    PASADENA 1-year open-label extension

    G. Pagano, A. Reyes, A. Monnet, M. Martinec, N. Shariati, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, K. Taylor, H. Svoboda, P. Fontoura, G. Kerchner, R. Doody, A. Bonni, T. Nikolcheva (Basel, Switzerland)

    Objective: To describe the results of PASADENA 1-year open-label extension (OLE). Background: Prasinezumab is a humanized monoclonal antibody that binds aggregated alpha-synuclein with the potential…
  • 2023 International Congress

    A Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants With Early Parkinson’s Disease (PADOVA): Rationale, Design, and Baseline Data

    T. Nikolcheva, G. Pagano, N. Pross, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, K. Seppi, A. Monnet, N. Shariati, L. Rutten-Jacobs, S. Zanigni, T. Kustermann, K. Taylor, D. Trundell, H. Svoboda, A. Bonni, P. Fontoura, R. Doody (BASEL, Switzerland)

    Objective: The study will evaluate the efficacy and safety of prasinezumab in individuals with early-stage Parkinson's disease (PD) on stable symptomatic therapy. Background: Available treatments…
  • 2023 International Congress

    Glycated alpha-synuclein and it emerging role in early onset of Parkinson’s disease

    S. Chatterjee, H. Thakkar, A. Khairnar, R. Shah (Gandhinagar, India)

    Objective: To elucidate, the molecular mechanism underlying glycated α-Syn mediated dopaminergic (DAergic) neurodegeneration in the substantia nigra (SN) via the AGE/RAGE signaling pathway. Background: Intracytoplasmic…
  • 2023 International Congress

    Impairment of SHH signaling in PD LRRK2 I1371V iPSC derived floor plate cells contribute to ontogenic origin of lower dopaminergic-neuron yield

    I. Datta, S. Jagtap, C. Potdar, K. Singh (Bengaluru, India)

    Objective: To estimate SHH responsiveness & signaling of Floor Plate Cells (FPCs) derived from LRRK2 I1371V PD patient-iPSCs along with its link with LRRK2 I1371V…
  • 2023 International Congress

    Artificial Intelligence to detect and classify tremors in patients with Parkinson’s disease and related conditions

    T. Elshourbagy, M. Hernandez, G. Mckay, J. Brasic (Cairo, Egypt)

    Objective: To develop a machine learning program to detect and classify tremors in patients with Parkinson's disease (PD) and related conditions. Background: PD is the…
  • 2023 International Congress

    SARS-CoV-2 infection exacerbates the cellular pathology in Parkinson’s disease progression

    HN. Choi, BN. Lee, YH. Che, MG. Ko, HM. Seong, MG. Jo, KS. Lyoo, YJ. Kim, SP. Yun (Jin-Ju, Republic of Korea)

    Objective: This study can provide an important insight for identification and prediction of long term neurological sequelae of SARS-CoV-2 infection and proper clinical management the…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 15
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley